At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 303 enrolled
Drug / intervention
Bimekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
In Brief
A Phase 2 clinical trial evaluating Placebo and Bimekizumab for Ankylosing Spondylitis. Completed, enrolled 303 participants across 74 sites in 10 countries.
Detailed Summary
This is a study to evaluate the efficacy and safety of different doses of bimekizumab in subjects with active Ankylosing Spondylitis (AS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
CountriesBulgaria, Canada, Czechia, Germany, Hungary, Poland, Russia, Spain, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
First PostedNov 2016
Primary CompletionOct 2017
Study CompletionAug 2018
TodayJul 2026
First PostedNov 15, 2016
Enrollment StartOct 1, 2016
Primary CompletionOct 1, 2017
Study CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 9.6 years ago
Interventions
Placeboother
Bimekizumabdrug
Bimekizumab in different dosages.